Immunization strategies for Clostridium difficile infections

Expert Review of Vaccines

Volumn 11, Issue 4, 2012, Pages 469-479

  Rebeaud, Fabien ^a   Bachmann, Martin F ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

bacterial toxins; Clostridium difficile; immunotherapy; infection; monoclonal antibody; nosocomial disease; treatment update; vaccine; virulence factor

Indexed keywords

ACAM CDIFF; BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN A ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXIN B ANTIBODY; CLOSTRIDIUM DIFFICILE VACCINE; CWP84 ANTIGEN; DNA VACCINE; FIDAXOMICIN; HYBRID PROTEIN; IC 84; IMMUNOGLOBULIN; METRONIDAZOLE; MK 3415; MK 6072; MONOCLONAL ANTIBODY; PLACEBO; SUBUNIT VACCINE; TOXIN ANTIBODY; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ACTIVE IMMUNIZATION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LOW DRUG DOSE; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW;

BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; IMMUNIZATION; VIRULENCE;

EID: 84860573425     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.18     Document Type: Review

References (82)

1. Hall IC, O'Toole E. Interstinal flora in new-born infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am. J. Dis. Child 49(2), 390-402 (1935).
2. Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin. Infect. Dis. 46(Suppl. 1), S4-S11 (2008). (Pubitemid 351323660)
3. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7(7), 526-536 (2009).
4. Final Report for Rates of Clostridium difficile for Ohio Hospitals and Nursing Homes. Final Report for Rates of Clostridium difficile for Ohio Hospitals and Nursing Homes. Ohio Department of Health, OH, USA (2006).
5. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect. Control Hosp. Epidemiol. 28(11), 1219-1227 (2007). (Pubitemid 47596558)
6. Mcdonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New Engl. J. Med. 353(23), 2433-2441 (2005). (Pubitemid 41770164)
7. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366(9491), 1079-1084 (2005). (Pubitemid 41338761)
8. Akerlund T, Persson I, Unemo M et al. Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J. Clin. Microbiol. 46(4), 1530-1533 (2008). (Pubitemid 351563610)
9. Carter GP, Douce GR, Govind R et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/ NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 7(10), e1002317 (2011).
10. Burns DA, Heeg D, Cartman ST, Minton NP. Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. Plos One 6(9), e24894 (2011).
11. Freeman J, Bauer MP, Baines SD et al. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 23(3), 529-549 (2010).
12. Bauer MP, Kuijper EJ, Van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15(12), 1067-1079 (2009).
13. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31(5), 431-455 (2010).
14. Pelaez T, Alcala L, Alonso R, Rodriguez- Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46(6), 1647-1650 (2002). (Pubitemid 34535177)
15. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New Engl. J. Med. 364(5), 422-431 (2011).
16. Mcfarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 101(4), 812-822 (2006).
17. Hickson M, D'Souza AL, Muthu N et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335(7610), 80 (2007).
18. Giesemann T, Egerer M, Jank T, Aktories K. Processing of Clostridium difficile toxins. J. Med. Microbiol. 57(Pt 6), 690-696 (2008). (Pubitemid 351842059)
19. Papatheodorou P, Zamboglou C, Genisyuerek S, Guttenberg G, Aktories K. Clostridial glucosylating toxins enter cells via clathrin-mediated endocytosis. PloS One 5(5), e10673 (2010).
20. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18(2), 247-263 (2005). (Pubitemid 40548293)
21. Greco A, Ho JG, Lin SJ, Palcic MM, Rupnik M, Ng KK. Carbohydrate recognition by Clostridium difficile toxin A. Nat. Struct. Mol. Biol. 13(5), 460-461 (2006). (Pubitemid 43881588)
22. Ho JG, Greco A, Rupnik M, Ng KK. Crystal structure of receptor-bindingC-terminal repeats from Clostridium difficile toxin A. Proc. Natl Acad. Sci. USA 102(51), 18373-18378 (2005). (Pubitemid 43011233)
23. Jank T, Giesemann T, Aktories K. Clostridium difficile glucosyltransferase toxin B-essential amino acids for substrate binding. J. Biol. Chem. 282(48), 35222-35231 (2007). (Pubitemid 350232434)
24. Pruitt RN, Chagot B, Cover M, Chazin WJ, Spiller B, Lacy DB. Structure-function analysis of inositol hexakisphosphateinduced autoprocessing in Clostridium difficile toxin A. J. Biol. Chem. 284(33), 21934-21940 (2009).
25. Reinert DJ, Jank T, Aktories K, Schulz GE. Structural basis for the function of Clostridium difficile toxin B. J. Mol. Biol. 351(5), 973-981 (2005). (Pubitemid 41133445)
26. Shen A, Lupardus PJ, Gersch MM et al. Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins. Nat. Struc. Mol. Biol. 18(3), 364-371 (2011).
27. Lyerly DM, Saum KE, Macdonald DK, Wilkins TD. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 47(2), 349-352 (1985). (Pubitemid 15169828)
28. Libby JM, Jortner BS, Wilkins TD. Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect. Immun. 36(2), 822-829 (1982). (Pubitemid 12101915)
29. Arnon SS, Mills DC, Day PA, Henrickson RV, Sullivan NM, Wilkins TD. Rapid death of infant rhesus monkeys injected with Clostridium difficile toxins A and B: physiologic and pathologic basis. J. Pediatr. 104(1), 34-40 (1984). (Pubitemid 14178457)
30. Cartman ST, Minton NP. A mariner-based transposon system for in vivo random mutagenesis of Clostridium difficile. Appl. Environ. Microbiol. 76(4), 1103-1109 (2010).
31. Heap JT, Cartman ST, Kuehne SA, Cooksley C, Minton NP. ClosTrontargeted mutagenesis. Meth. Mol. Biol. 646, 165-182 (2010).
32. Lyras D, O'Connor Jr, Howarth PM et al. Toxin B is essential for virulence of Clostridium difficile. Nature 458(7242), 1176-1179 (2009).
33. Kuehne SA, Cartman ST, Minton NP. Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut microbes 2(4), 252-255 (2011).
34. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467(7316), 711-713 (2010).
35. Ballard JD. Medical microbiology: a toxin contest. Nature 467(7316), 665-666 (2010).
36. Carter GP, Awad MM, Kelly ML, Rood JI, Lyras D. TcdB or not TcdB: a tale of two Clostridium difficile toxins. Future Microbiol. 6(2), 121-123 (2011).
37. Drudy D, Fanning S, Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile. Int. J. Infect. Dis. 11(1), 5-10 (2007). (Pubitemid 44937660)
38. Chaves-Olarte E, Freer E, Parra A, Guzman-Verri C, Moreno E, Thelestam M. R-Ras glucosylation and transient RhoA activation determine the cytopathic effect produced by toxin B variants from toxin A-negative strains of Clostridium difficile. J. Biol. Chem. 278(10), 7956-7963 (2003). (Pubitemid 36800533)
39. Lanis JM, Barua S, Ballard JD. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog. 6(8), e1001061 (2010).
40. Schwan C, Stecher B, Tzivelekidis T et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog. 5(10), e1000626 (2009).
41. Bacon AE 3rd, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibioticassociated diarrhea. Diagn. Microbiol. Infect. Dis. 18(4), 205-209 (1994). (Pubitemid 24231268)
42. Kelly CP, Pothoulakis C, Orellana J, Lamont JT. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 102(1), 35-40 (1992).
43. Viscidi R, Laughon BE, Yolken R et al. Serum antibody response to toxins A and B of Clostridium difficile. J. Infect. Dis. 148(1), 93-100 (1983). (Pubitemid 13039317)
44. Kelly CP, Kine L. The host immune response to Clostridium difficile. J. Med. Microbiol. 60, 1070-1079 (2011).
45. Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 13(3), 97-101 (1985). (Pubitemid 15030800)
46. Johnson S, Sypura WD, Gerding DN, Ewing SL, Janoff EN. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect. Immun. 63(8), 3166-3173 (1995).
47. Leav BA, Blair B, Leney M et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28(4), 965-969 (2010).
48. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect. Immun. 59(6), 2215-2218 (1991).
49. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 66(5), 2018-2025 (1998). (Pubitemid 28194097)
50. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, Lamont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J. Pediatr. 118(4 Pt 1), 633-637 (1991).
51. Salcedo J, Keates S, Pothoulakis C et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41(3), 366-370 (1997). (Pubitemid 27428197)
52. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig. Dis. Sci. 56(1), 19-26 (2011).
53. Babcock GJ, Broering TJ, Hernandez HJ et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74(11), 6339-6347 (2006). (Pubitemid 44657416)
54. Lowy I, Molrine DC, Leav BA et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. New Engl. J. Med. 362(3), 197-205 (2010).
55. Fernie DS, Thomson RO, Batty I, Walker PD. Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev. Biol. Stand. 53, 325-332 (1983).
56. Giannasca PJ, Zhang ZX, Lei WD et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect. Immun. 67(2), 527-538 (1999). (Pubitemid 29059183)
57. Kim PH, Iaconis JP, Rolfe RD. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect. Immun. 55(12), 2984-2992 (1987). (Pubitemid 18008268)
58. Sauerborn M, Leukel P, Von Eichel- Streiber C. The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiol. Lett. 155(1), 45-54 (1997). (Pubitemid 28020288)
59. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol. Chem. 389(5), 521-536 (2008). (Pubitemid 351874198)
60. Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect. Immun. 65(7), 2941-2949 (1997). (Pubitemid 27264128)
61. Permpoonpattana P, Hong HA, Phetcharaburanin J et al. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect. Immun. 79(6), 2295-2302 (2011).
62. Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 27(27), 3598-3604 (2009).
63. Torres JF, Lyerly DM, Hill JE, Monath TP. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect. Immun. 63(12), 4619-4627 (1995).
64. Ward SJ, Douce G, Dougan G, Wren BW. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect. Immun. 67(10), 5124-5132 (1999). (Pubitemid 29455282)
65. Ward SJ, Douce G, Figueiredo D, Dougan G, Wren BW. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect. Immun. 67(5), 2145-2152 (1999). (Pubitemid 29200465)
66. Aboudola S, Kotloff KL, Kyne L et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect. Immun. 71(3), 1608-1610 (2003). (Pubitemid 36254357)
67. Kotloff KL, Wasserman SS, Losonsky GA et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect. Immun. 69(2), 988-995 (2001). (Pubitemid 32109565)
68. Fagan RP, Janoir C, Collignon A, Mastrantonio P, Poxton IR, Fairweather NF. A proposed nomenclature for cell wall proteins of Clostridium difficile. J. Medical Microbiol. 60, 1225-1228 (2011).
69. Cerquetti M, Molinari A, Sebastianelli A et al. Characterization of surface layer proteins from different Clostridium difficile clinical isolates. Microb. Pathog. 28(6), 363-372 (2000).
70. Fagan RP, Albesa-Jové D, Qazi O, Svergun DI, Brown KA, Fairweather NF. Structural insights into the molecular organization of the S-layer from Clostridium difficile. Mol. Microbiol. 71(5), 1308-1322 (2009).
71. O'Brien JB, Mccabe MS, Athie-Morales V, Mcdonald GS, Ni Eidhin DB, Kelleher DP. Passive immunisation of hamsters against Clostridium difficile infection using antibodies to surface layer proteins. FEMS Microbiology Lett. 246(2), 199-205 (2005). (Pubitemid 40731481)
72. Ni Eidhin DB, O'Brien JB, Mccabe MS, Athie-Morales V, Kelleher DP. Active immunization of hamsters against Clostridium difficile infection using surfacelayer protein. FEMS Immunol. Med. Microbiol. 52(2), 207-218 (2008). (Pubitemid 351248426)
73. Janoir C, Pechine S, Grosdidier C, Collignon A. Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins. J. Bacteriol. 189(20), 7174-7180 (2007). (Pubitemid 47557330)
74. Pechine S, Janoir C, Collignon A. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J. Clin. Microbiol. 43(10), 5018-5025 (2005). (Pubitemid 41483998)
75. Pechine S, Deneve C, Le Monnier A, Hoys S, Janoir C, Collignon A. Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen. FEMS Immunol. Med. Microbiol. 63(1), 73-81 (2011).
76. Pechine S, Janoir C, Boureau et al. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine 25, 3946-3954 (2007). (Pubitemid 46617001)
77. Sandolo C, Pechine S, Monnier AL et al. Encapsulation of Cwp84 into pectin beads for oral vaccination against Clostridium difficile. Eur. J. Pharm. Biopharm. 79(3), 566-573 (2011).
78. Seeberger PH, Werz DB. Synthesis and medical applications of oligosaccharides. Nature 446(7139), 1046-1051 (2007). (Pubitemid 46676067)
79. Ganeshapillai J, Vinogradov E, Rousseau J, Weese JS, Monteiro MA. Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. Carbohydr. Res. 343(4), 703-710 (2008).
80. Danieli E, Lay L, Proietti D, Berti F, Costantino P, Adamo R. First synthesis of C. difficile PS-II cell wall polysaccharide repeating unit. Org. Lett. 13(3), 378-381 (2011).
81. Oberli MA, Hecht ML, Bindschadler P, Adibekian A, Adam T, Seeberger PH. A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem. Biol. 18(5), 580-588 (2011).
82. Brydak LB, Machala M, Mysliwska J, Mysliwski A, Trzonkowski P. Immune response to influenza vaccination in an elderly population. J. Clin. Immunol. 23(3), 214-222 (2003). (Pubitemid 36521215)